Freenome, Inc. operates as an early detection company, which engages in the development of blood-based screening tests to detect cancer. Its proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. The company was founded by Riley Ennis in 2014 and is headquartered in Brisbane, CA.
Sector:
Health Technology
Industry:
Medical Specialties
Employees:
3
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Freenome Inc. market cap is $1.04B.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Freenome Inc. 52 week high is $17.50 as of November 22, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Freenome Inc. 52 week low is $9.28 as of November 22, 2026.
Freenome Inc. stock price today is $9.36.
Freenome Inc. stock price yesterday was $9.93.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Freenome Inc.'s P/E ratio is 18.82.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Freenome Inc. P/B ratio is 2.156.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Freenome Inc. 50-day moving average is $13.40.